pathways

A unique collection of 1283 endogenous metabolism-related compounds for research in endogenous metabolism-related diseases and drug screening.

A unique collection of 1940 GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

A unique collection of 812 promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine;

A unique collection of 910 DNA Damage & Repair related compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1268 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2720 kinase inhibitors regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;

Well-chosen 1246 compounds with unique structures targeting nervous system;

A unique collection of 449 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening；

A unique collection of 1702 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study；

A unique collection of 1040 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening;

A unique collection of 2540 compounds targeting CNS signaling for high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 250 compounds targeting chromatin remodeling pathway for high throughput screening (HTS) and high content screening (HCS);

Well-chosen 338 GPCR targeting compounds with unique structures;

A unique collection of 986 compounds with anti-AD activities or acting on main drug targets of AD can be used for HTS and HCS.

A unique collection of 779 ferroptosis signaling pathway related compounds, a powerful tool for new target identification, drug discovery, and mechanism study；

A unique collection of 406 cancer cell differentiation inducing compounds for high throughput and high content screening;

A collection of 1246 TCM monomers with anti-inflammatory activity or targeting molecular therapeutic targets in inflammation, a powerful tool for drug discovery and mechanism study；

A unique collection of 604 compounds targeting cytokine signaling for high throughput screening and high content screening for drug discovery;

A unique collection of 140 calcium channel blockers and agonists for high throughput and high content screening;

A unique collection of 4880 anti-aging compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related diseases;

A unique collection of 1939 compounds with anti-breast cancer therapeutic activity or targeting breast cancer’s major signaling pathways, can be used for anti-breast cancer drug discovery and mechanism study；

Well-chosen 667 compounds with unique structures targeting DNA damage & repair;

A unique collection of 580 compounds derived from traditional Chinese medicines (TCMs) for promoting blood circulation and removing blood stasis.

A unique collection of 149 neuroregeneration related compounds for high throughput and high content screening;

A unique collection of 1813 reprogramming signaling pathway-related bioactive small molecule compounds for high-throughput, high-content screening.

A unique collection of 317 osteogenesis related compounds for high throughput and high content screening;

A unique collection of 4720 anti-inflammation compounds effective for high throughput screening and high content screening.

A unique collection of 574 fluorochemicals that can be used for high through-put screening (HTS) and high content screening (HCS);

A unique collection of 59 chemokines or chemokine receptors targeted compounds for high throughput and high content screening;

A unique collection of 1336 HIF-1 related small chemicals can be used for drug discovery in ischemic disease and cancer and related mechanism studies；

A unique collection of 8328 inhibitors for research in cell signaling, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 385 bioactive lipids related compounds for high throughput screening (HTS) and high content screening (HCS), including Agonists & Antagonists, Endocannabinoids, Farnesyl geranylgeranyl derivates, HETEs deHETEs, hepoxilins, Polyunsa

76 exosome-related compounds that can be used for high-throughput and high-content screening.